Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.

Liver international : official journal of the International Association for the Study of the Liver - 1 Jan 2011

Petta Salvatore, Craxì Antonio

Abstract excerpt

Current guidelines recommend that patients with genotype 2 (G2) and 3 (G3) chronic hepatitis C be treated with pegylated interferon (PEG-IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks, resulting in a sustained virological response (SVR) rate of approximately 80%. Considering these high response rates, several recent randomized trials have assessed whether shorter treatment (12-16 weeks) could be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis C
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 21205136
DOI: 10.1111/j.1478-3231.2010.02382.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.PMID 21205136Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review.Semantic proximity Read ↗

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.Semantic proximity Read ↗

'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?Semantic proximity Read ↗

Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.Semantic proximity Read ↗

What's new in HCV genotype 2 treatment.Semantic proximity Read ↗

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.Semantic proximity Read ↗

Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

Hepatitis C treatment: shorter and better?Semantic proximity Read ↗

Optimal treatment duration for patients with HCV genotype 1 infection.Semantic proximity Read ↗

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.